EXPANDING THE POSSIBILITIES

BioHybrid Solutions (BHS), is a transformational platform company that develops next-generation NanoArmored protein-polymer conjugates. Using proprietary technology originally developed at Carnegie Mellon University, proteins are rationally and precisely modified with polymers to dramatically improve their stability and performance.

The BioHybrid Solutions Platform

The BHS platform can be applied across the $150 billion biocatalysis and therapeutics marketplace to dramatically improve protein performance. In addition, we also open the door to new routes of administration (such as injectable to oral), improved pharmacodynamics/pharmacokinetics, and reduced immunogenicity.

It started with a question

BioHybrid Solutions was created in 2016 to solve a problem in human wellness: how can we improve protein therapeutics with chemical building blocks that evade the immune system and remain functional in the human body? Proteins, the workhorses of living systems, are the foundation of advances in pharmaceuticals. But these extraordinary biomacromolecules are highly sensitive to their environment: stomach acid and the body’s natural temperature for example. This effort has gone through phases of discovery during which proteins and enzymes have been immobilized on solid supports, embedded in polymers, reacted with polymers, and protein engineered by random or site-directed mutagenesis.

Pioneers in Protein Engineering

Alan Russell and Carnegie Mellon University (CMU) colleague Krzysztof Matyjaszewski have pioneered this field while researching unique ways to develop very dense polymer shields for proteins using controlled chemistry. The past several years have been spent perfecting this chemistry, aided by major investments. In 2015, CMU launched the Center for Polymer-Based Protein Engineering, which Drs. Russell and Matyjaszewski co-direct. In the spring of 2016, they spun out Biohybrid Solutions with the goal of deploying their technology to enable better therapeutics that move beyond protein PEGylation.

The 'Grafted From' Approach

The Biohybrid team has mastered how to covalently couple or display multiple small molecule initiators onto a protein and then grow polymers from those sites. Using this ‘grafted from’ approach, they have engineered protein-polymer hybrids with stimuli-responsive polymers that respond to external triggers, such as temperature and pH, all while maintaining biologic activity. Simply put: BHS has developed therapeutic solutions that will make life-saving and quality-of-life drugs work better.

The Next Generation of Long-Lived Protein Therapeutics

1968

Frank Davis proposes protein-polymer conjugates

1981

Enzon founded

1983

Ed Merrill identifies Polyethylene Oxide as a Biomaterial

1990

Nektar Therapeutics founded

1990

FDA Approves first PEGylated Drug

1992

Shearwater Polymers founded by Milton Harris

2005

Russell and Matyjaszewski invent protein-ATRP

2016

BioHybrid Solutions (BHS) was founded

2018

BHS awarded first contract to develop automation and high throughput screening of protein polymer conjugates

Our Team

Our award-winning team of co-founders includes one of the most cited chemists in modern history, who was recently elected to the National Academy of Science, as well as the founder of Carnegie Mellon University’s Center for Polymer-Based Protein Engineering. By combining the power of computational science, synthetic chemistry and biology, the Biohybrid team is rapidly growing. Their new set of tools that overcome the limitations of biomacromolecular systems are being sought out by federal agencies and pharmaceutical companies. A recent $30 million dollar partnership with the U.S. Department of Defense is helping to propel the breadth and depth of NanoArmored™ therapeutic applications.

Alan Russell, Ph.D.

Founder and Chief Executive Officer

Dr. Alan Russell (Ph.D., Imperial College) is the Highmark Distinguished Career Professor in the Department of Chemical Engineering & the Director of the Disruptive Health Technology Institute at Carnegie Mellon University. Dr. Russell is also the CEO of BioHybrid Solutions, LLC and Chairman of the Board of Directors of YouScript, Inc. Dr. Russell has broad experience at the interface of science, healthcare and commercialization.

Krzysztof (Kris) Matyjaszewski, Ph.D.

Founder and Chief Scientific Officer

Krzysztof (Kris) Matyjaszewski, Ph.D., professor in the department of chemistry at the Mellon College of Science, Carnegie Mellon University, is highly regarded internationally recognized polymer chemist who has yielded significant innovations in polymer chemistry. He is perhaps best known for the discovery of atom radical transfer polymerization (ATRP), a novel method of polymer synthesis that has revolutionized the way macromolecules are made.

Antonina Simakova, Ph.D.

Founder and Vice President of Research

Antonina Simakova completed her PhD and post-doctoral fellowship in the laboratory of Prof. Matyjaszewski at CMU. Her PhD work focused on the development of novel aqueous ATRP processes for biomedical applications. Previously, she spent two years working in an influenza virus laboratory, studying influenza strain distribution and investigating polyaniline as adsorbent for viruses. Dr. Simakova directs R&D for BHS, overseeing all laboratory operations.

Career Opportunities

Interested in working for us?

Click this link to view the current open positions at BioHybrid Solutions.

Discover a better solution For therapeutics and protein engineering